Oppenheimer | GenomeWeb

Oppenheimer

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer, investment firm William Blair today downgra

NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investment bank Oppenheimer has initiated coverage of Genomic Health, Thermo Fisher Scientific, and Fluidigm.

According to Oppenheimer, Sequenom will hire 20 sales representatives for the test by the end of August and has contacted 28 payors for reimbursement of the test, of which 25 have responded with "encouraging" feedback.

"CMS is the decision-maker here regarding fee schedule placement [of genetic tests] and we are pleased they are recognizing the importance … of having stakeholders provide input on the questions they've asked," said David Mongillo, vice president for policy and medical affairs at the American Clinical Laboratory Association.

The new revenue estimates come amid concerns about the effect of the Japanese earthquake, competition in the next-generation sequencing space, and government funding on the company's business.

An Oppenheimer analyst noted the quality of Complete Genomics' data, a continued demand for sequencing service providers, and the progression of sequencing into clinical applications.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.